Institute of Reproductive Medicine, HB-36/A/3, Salt Lake City, Sector-III, Kolkata, Kolkata 700106, India.
Institute of Reproductive Medicine, HB-36/A/3, Salt Lake City, Sector-III, Kolkata, Kolkata 700106, India.
Reprod Biomed Online. 2019 Jan;38(1):13-21. doi: 10.1016/j.rbmo.2018.09.014. Epub 2018 Oct 26.
Reports on the effect of adenomyosis on assisted reproductive technology (ART) outcomes are conflicting. Does presence of adenomyosis affect reproductive outcome in IVF cycles in women pretreated with gonadotrophin releasing hormone (GnRH) agonist?
In this retrospective cohort study, 973 women were divided into four groups: only endometriosis (n = 355); endometriosis and adenomyosis (n = 88); adenomyosis alone (n = 64); and tubal factor infertility as controls (n = 466). The pregnancy outcome parameters (clinical pregnancy, miscarriage rate, live birth rate) were compared between these groups.
The clinical pregnancy rate was 36.62% in women with endometriosis alone, 22.72% in women with endometriosis and adenomyosis, 23.44% in women who only had adenomyosis and 34.55% in controls. Miscarriage rates were as follows: 14.62%, 35%, 40% and 13.04%, respectively. Live birth rates were 27.47% in controls; 26.48% in women with only endometriosis; 11.36% in women with endometriosis and adenomyosis; and 12.5% in women with only adenomyosis. Live birth was observed to be less in adenomyosis groups compared with controls and women with only endometriosis. No significant difference was observed in clinical pregnancy, miscarriage or live birth rate between controls and women with only endometriosis. Live birth rate was significantly different between controls and women with adenomyosis only (P = 0.01) and women with endometriosis and adenomyosis (P = 0.002).
Presence of adenomyosis seems to have adverse effects on IVF outcomes in clinical pregnancy rate, live birth rate and miscarriage rate. Screening for adenomyosis might be considered before ART so that the couple has better awareness of the prognosis.
关于子宫腺肌病对辅助生殖技术(ART)结局的影响的报告存在矛盾。在接受促性腺激素释放激素(GnRH)激动剂预处理的 IVF 周期中,存在子宫腺肌病是否会影响女性的生殖结局?
在这项回顾性队列研究中,973 名女性分为四组:单纯子宫内膜异位症(n=355);子宫内膜异位症和子宫腺肌病(n=88);单纯子宫腺肌病(n=64);和输卵管因素不孕作为对照组(n=466)。比较这些组之间的妊娠结局参数(临床妊娠、流产率、活产率)。
单纯子宫内膜异位症患者的临床妊娠率为 36.62%,子宫内膜异位症和子宫腺肌病患者为 22.72%,单纯子宫腺肌病患者为 23.44%,对照组为 34.55%。流产率分别为:14.62%、35%、40%和 13.04%。活产率分别为:对照组 27.47%;单纯子宫内膜异位症患者 26.48%;子宫内膜异位症和子宫腺肌病患者 11.36%;单纯子宫腺肌病患者 12.5%。与对照组和单纯子宫内膜异位症患者相比,子宫腺肌病组的活产率较低。对照组与单纯子宫内膜异位症患者之间的临床妊娠率、流产率或活产率无显著差异。对照组与单纯子宫腺肌病患者(P=0.01)和子宫内膜异位症和子宫腺肌病患者(P=0.002)之间的活产率差异有统计学意义。
子宫腺肌病的存在似乎对 IVF 的临床妊娠率、活产率和流产率有不良影响。在进行 ART 之前可能需要对子宫腺肌病进行筛查,以便夫妇更好地了解预后。